Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company.
A number of research firms have recently weighed in on STVN. Morgan Stanley initiated coverage on shares of Stevanato Group in a research note on Monday. They set an “equal weight” rating and a $24.00 price target on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Stevanato Group in a research report on Monday, November 24th.
View Our Latest Research Report on STVN
Institutional Trading of Stevanato Group
Stevanato Group Stock Down 2.1%
Stevanato Group stock opened at €22.11 on Friday. The stock’s 50 day moving average price is €24.35 and its 200 day moving average price is €24.28. Stevanato Group has a 1-year low of €17.81 and a 1-year high of €28.00. The company has a market cap of $6.69 billion, a PE ratio of 38.78, a price-to-earnings-growth ratio of 2.22 and a beta of 0.57. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.89 and a quick ratio of 1.30.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
See Also
- Five stocks we like better than Stevanato Group
- Why is the Ex-Dividend Date Significant to Investors?
- Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?
- Industrial Products Stocks Investing
- Checkmate in the Cloud: ServiceNow’s Shopping Spree
- How to Invest in Biotech Stocks
- The Contrarian Case for MSTR Amid MSCI Delisting Debacle
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
